Author Flip


12900article: Onivyde (Irinotecan Liposome Injection) a New Treatment Option for Patients with Metastatic Pancreatic Cancer
13571article: New Survey: Physicians Are Not Addressing Financial Distress in Patients with Multiple Myeloma
13571article: A New Paradigm for Survivorship Care: Assessing the Patient’s Priorities
703article: Regular Aspirin Use Reduces the Risk for Prostate Cancer Death
192article: Increased Physical Activity May Help Extend Survival After Prostate Cancer Diagnosis
703article: Myeloablative Conditioning Remains Standard of Care in Patients with Myelodysplastic Sydrome
13580article: Rituximab Boosts Chemotherapy Benefit in Patients with B-Cell Precursor ALL
13580article: Pembrolizumab Shows Promise in Multiple Myeloma
12448,13640article: Big Data in Cancer Care: Limitations of Drug Claims
13571article: Clinical Advances with Targeted Therapies for CLL Also Carry High Economic Burden
13580article: First-in-Human CAR T-Cell Trial Demonstrates Activity in Multiple Myeloma
703article: Inotuzumab Ozogamicin Shows Promise in Older Patients with Acute Lymphoblastic Leukemia
192article: Biomarker Panel May Aid Early Detection of Colorectal Cancer
703article: Liquid Biopsy Characterizing Circulating Tumor Cells Can Aid Treatment Selection in Prostate Cancer
192article: Atezolizumab, a PD-L1 Inhibitor, Shows Impressive Results in Metastatic Urothelial Cancer
13580article: A 3-Drug Regimen the Preferred Approach in Newly Diagnosed Multiple Myeloma
13588article: New Biosimilar Demonstrates Equivalence and Noninferiority to Pegfilgrastim
13571article: Anthem’s Response to Survivorship Medicine: Reimbursement Based on Care Coordination and Patient Outcomes
643,13629article: The NCCN Evidence Blocks and Clinical Practice Guidelines: Identifying Truth
637article: Value-Based Care Must Be Linked to Improved Clinical Outcomes
703article: Venetoclax Shows Strong Activity in CLL
192article: CAR T-Cell Therapy Highly Active in Various Lymphomas
703article: Checkpoint Inhibitors in Lymphoma: A New Universe
13571article: Immunotherapy with Blinatumomab Prolongs Survival in Acute Lymphoblastic Leukemia
703article: Ibrutinib a New Standard of Care for Elderly Patients with Chronic Lymphocytic Leukemia
703article: Idelalisib Improves Survival When Added to Bendamustine plus Rituximab in Patients with CLL
13571article: Nilotinib Yields Better Rates of Molecular Response Than Imatinib in Frontline Setting
13580article: Daratumumab Improves Overall Survival in Multiple Myeloma
13580article: Consistent Benefit Over Time in Elotuzumab Studies
13580article: All-Oral Regimen May Become a New Standard of Care in Advanced Multiple Myeloma
13571article: Measuring Value in Healthcare to Improve Quality
13571article: Redesigning the Payment Model for Acute Leukemia: Benefits and Challenges of the Episode-of-Care Model
13571article: Value-Based Purchasing: Implications for Hematology
703article: The Hematologic Drug Pipeline: Exciting New Treatment Options Looming
13571article: Clinical Pathways and the Oncology Medical Home: First Steps to Value-Based Patient Care
703article: Midostaurin the First Targeted Therapy to Improve Survival in AML: Potentially Practice-Changing
13580article: Multiple Myeloma Therapy in 2015: “An Extraordinary Moment in Oncology”
12900article: Keytruda (Pembrolizumab) First PD-1 Inhibitor Approved for the Treatment of Patients with Metastatic Non–Small-Cell Lung Cancer Expressing PD-L1
15article: Two Studies Point to Inadequate Evidence Supporting Many FDA Drug Approvals
144article: Getting to Value-Based Cancer Care in the ’Omics Era Requires Data Integration
13575article: Promising Locoregional Therapies for Hepatocellular Carcinoma and Metastatic CRC
13571article: Treating Sexual Dysfunction in Breast Cancer Survivors
13571article: Addressing Fertility Issues in Patients with Breast Cancer
13622article: Aprepitant Reduces Cough Severity in Patients with Lung Cancer
703article: Teamwork Improves End-of-Life Care, Saves Money
144article: Urine Biopsies Detect Early Mutations in Patients with Advanced Cancers
13622article: Personalized Medicine a Vital Aspect of Palliative Care
13622article: ASCO/AAHPM Guidance Statement Could Standardize Palliative Care in Oncology
144article: Oncology Medical Home Shows Significant Cost-Savings, Improved Care Delivery
703article: Genomic Test Supports Treatment Decisions in Prostate Cancer
13622article: Family Patient-Related Factors Main Barriers to End-of-Life Discussions
13567article: American Cancer Society Updates Breast Cancer Screening Guidelines for Women at Average Risk
13588article: 80-Gene Assay Identifies Distinct Triple-Positive Breast Cancer Subtypes, Guides Therapy Selection
703article: Men’s Health Supplements Have No Value for Patients with Prostate Cancer
13627article: Value-Based Oncology Center of Excellence Model
703article: Chemotherapy Safe During Pregnancy in Second and Third Trimesters
13617article: Consuming ?4 Cups of Coffee Improves Outcomes in Patients with Stage III Colon Cancer
13575article: Aprepitant Improves Emesis Control in Patients with Colorectal Cancer
13575article: Systemic Therapy plus Radiofrequency: Ablation Survival Benefit in Colorectal Liver Metastases
13575article: Ramucirumab Confers Survival Benefit in Some Patients with Hepatocellular Carcinoma
15article: Screening in Younger First-Degree Relatives of Patients with CRC
13588article: MRI Screening of Women at Average Risk for Breast Cancer Improves Detection
703article: Significant Benefits Seen with 2 New Options for Patients with Renal-Cell Carcinoma
13590article: The NCCN New Tool to Assess Value Discourages Patients’ Hope
144article: Next-Generation Sequencing Propelling Forward Cancer Knowledge, Therapy
13626article: New Guidelines for Breast Cancer Screening Still Not a Definitive Answer for Women Aged >40 Years
703article: Everolimus, 177Lu-DOTATATE Potentially 2 Practice-Changing Options in NETs
144article: NCCN Incorporates Affordability Criteria in Its Clinical Guidelines to Assess Value of Cancer Therapies
144article: Value Proposition of Oncology Pharmaceuticals: Drug Manufacturers Increasing Focus on Patient Support
13622article: Current Practice Least Cost-Effective Option in Prostate Cancer Management
15article: Whole-Brain Radiotherapy for Brain Metastases Is Cost-Effective
13580article: Using Genetics to Guide Pembrolizumab Therapy in CRC
13622article: NEXT Study: Biosimilar Filgrastim an Effective Alternative for Chemotherapy-Induced Neutropenia
703article: Atezolizumab: Another Immunotherapy for Lung Cancer?
13618,13620,13619,13621article: ASCO’s Value Framework: Is It All About the Drugs?
144article: An Accountable Payment Model a “Win-Win-Win” Solution to Value-Based Care
13617article: Breaking Bad News to Patients with Cancer: Oncologists’ Emotional Burden and Need for Support Systems
13616article: AstraZeneca Commentary on Oncology Value Tools
703article: Patients with Early Breast Cancer and Low Oncotype DX Scores Can Skip Chemotherapy
2096article: Controlled Ovarian Hyperstimulation Safe in Patients with Breast Cancer
144article: Oncology Medical Home Accreditation by Community Oncology Alliance Making Progress
144article: Oncology Specialty Pharmacy Promotes the Coordination of Care
2096article: PROCLAIM Study Fails to Identify Best Regimen for Locally Advanced Lung Cancer
2096article: SELECT: Lenvatinib Improves Outcomes as First-Line Treatment in Older Patients with Thyroid Cancer
13571article: Immunotherapies Steal the Show at ASCO 2015
13567article: Patients with Cancer Eager to Discuss Costs of Care with Their Oncologists
13567article: Medical and Psychosocial Impact of Oral Therapy on Patients with Metastatic Castration-Resistant Prostate Cancer
2096article: “Designer Drug” Rociletinib Shows Encouraging Results in Patients with NSCLC and T790M Mutation
2096article: Molecular Signature for Neuroendocrine Prostate Cancer Represents Progress
611article: My Struggle to Understand the Many Definitions of Value
13590article: Transforming Medicine: TMed Will Match People with Life-Threatening Illnesses to Best Treatments, in Real Time
144article: Oncology Pipeline Full, and Not Just with Immunotherapies
144article: Enzalutamide Outperforms Bicalutamide in 2 Trials of Prostate Cancer
13571article: Communication with Oncologists, Not Cost, Tops Patients’ Value Priorities
12900article: Ibrance (Palbociclib): First CDK4 and CDK6 Inhibitor FDA Approved for the Treatment of Postmenopausal Women with Metastatic Breast Cancer
144article: Personalized Medicine Affordability Lies in Enhanced Predictors of Response to Therapy
144article: High-Value Narrow Networks and Patient Safety Organizations the Future of Cancer Care
703article: Combination of PARP and PI3K Inhibitors Share a Genomic Landscape in Breast and Ovarian Cancers
144article: Cell Surface Amino Acid Potential as Prostate Cancer Biomarker
703article: GADOLIN Trial: Obinutuzumab an Effective Treatment for Indolent Lymphoma